CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/pf.v10i5.835
Abstract
The article presents a case of successful use of therapeutic monoclonal antibodies to interleukin 1 (canakinumab) at severe systemic juvenile idiopathic arthritis. Canakinumab treatment promptly provided reduction in clinical and laboratory disease activity indicators, increase in life quality, development of inactive disease stage and allowed avoiding prescription of glucocorticoids.
About the Authors
R. V. Denisova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Center of Children’s Health, Moscow, Russian Federation
First Sechenov Moscow State Medical University, Moscow, Russian Federation
Russian Federation
PhD, Professor, head of the rheumatology department at the SCCH, dean of the pediatrics faculty at the First Sechenov MSMU
Russian Federation
PhD, Professor, head of the rheumatology department at the SCCH, dean of the pediatrics faculty at the First Sechenov MSMU
T. V. Sleptsova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Cassidy J. T., Petty R. E. Juvenile idiopathic arthritis. In Cassidy J. T., Petty R. E. eds. Textbook of pediatric rheumatology, 6th edn. Philadelphia, WB Saunders, 2011.
2. Prakken B., Albani S., Martini A. Juvenile idiopathic arthritis. Lancet. 2011; 377: 2138–49.
3. Bzarova T. M., Alekseeva E. I., Peterkova V. A. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (5): 13–18.
4. Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 2007; 19: 477–81.
5. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 2005; 201: 1479–86.
6. Baranov A. A., Alekseeva E. I., Bzarova T. M. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (1): 37–56.
7. Gattorno M., Pelagatti M. A., Meini A., Obici L., Barcellona R., Federici S. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor–associated periodic syndrome. Arthritis Rheum. 2008; 58: 1516–20.
8. Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S. et al. The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58: 1505–15.
9. Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 2011; 70: 747–54.
10. Nigrovic P. A., Mannion M., Prince F. H., Zeft A., Rabinovich C. E., van Rossum M. A. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011; 63: 545–55.
11. Nicolino R., Pierre Q., Nico W. et al. A Phase II, Multicenter, Open-Label Study Evaluating Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features. Arthritis & Rheumatism. 2012; 64 (2): 557–567.
12. Nicolino R., Hermine I., Brunner et al. Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. N. Engl. J. Med. 2012; 367: 2396–406.
13. Namazova-Baranova L. S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (4): 15–24.
Review
For citations:
Denisova R.V., Alexeeva E.I., Sleptsova T.V. CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. Pediatric pharmacology. 2013;10(5):111-114. https://doi.org/10.15690/pf.v10i5.835
Views:
861
Email this article 